Mesa Laboratories (MLAB) CFO John Sakys Buys $217K of Stock

John Sakys, the Chief Financial Officer of Mesa Laboratories, Inc. (MLAB on the NasdaqGS), bought 2,282 shares of the company on June 18, 2026. This transaction, valued at roughly $217,018, was disclosed in a recent SEC filing. The buy occurred at a price of $95.10 per share and was not conducted under a pre-arranged Rule 10b5-1 trading plan.

Insider Buying and Selling at Mesa Laboratories, Inc.

The purchase by Sakys was just one part of a busy week for company executives. On the same day, June 18, 2026, CAO Lyndsey Elizabeth Crennen bought 263 shares at $95.10 and sold 233 shares. SVP of Operations Brian David Archbold was also active that day, purchasing 3,324 shares at $95.10 while selling 2,480 shares. Later, on June 22, 2026, both Crennen and Archbold sold additional shares at a price of $89.50. Specifically, Crennen sold 442 shares while Archbold sold 2,516 shares. These trades suggest a period of active portfolio rebalancing among the leadership team.

Mesa Laboratories Stock Performance

On Tuesday, shares of Mesa Laboratories were trading at $93.23. The stock has experienced a wide range over the last year, with a high of $132.70 and a low of $63.48. Currently, the price sits just below its 200-day moving average of $97.02, a level many investors watch to judge long-term trends. The company has a forward P/E ratio of 12.84, suggesting that while current profits are thin, the market expects earnings to strengthen in the coming year.

Recent Earnings and Growth

In its most recent financial reports, Mesa Laboratories posted annual revenue of $249.72 million, representing a modest growth of 0.01%. The company remains profitable with a net margin of 1.92% and earnings per share of $0.85. Its return on equity stands at roughly 2.66%. Investors are now looking toward November 5, 2026, when the company is scheduled to release its next set of quarterly results.

Dividend Payments

Mesa Laboratories continues to return capital to its shareholders through a regular dividend. The company pays an annual rate of $0.64 per share, which provides a yield of 0.5%. This payout represents about 75.3% of the company's earnings, showing a commitment to maintaining steady payments even as it navigates a changing market for scientific instruments.

Analysts Set New Price Targets

Financial firms have been adjusting their expectations for the stock recently. On August 14, 2026, Wells Fargo maintained an Equal-Weight rating on the stock but raised its price target from $94.00 to $110.00. Across the two analysts who cover the company, the average price target is $117.50, which is significantly higher than where the stock trades today.

About Mesa Laboratories

Mesa Laboratories designs and sells quality control tools used in the pharmaceutical and healthcare sectors. Its products help ensure that sterilization and disinfection processes are working correctly, and it also provides genetic analysis tools for clinical labs. This CFO purchase comes at a time when the company is focused on its biopharmaceutical development and calibration segments.

What's Ahead for Mesa Laboratories, Inc.

While insider buying like the trade from John Sakys can show confidence in the company's direction, it is only one piece of the puzzle. Investors will likely keep a close eye on the November 5 earnings report to see if the company's revenue growth can accelerate. For now, the stock remains in a period of consolidation as it trades between its recent highs and lows.